The mission of the Thrombosis Program is: To provide the best possible medical care to patients with thrombosis (blood clots) and individuals with thrombophilia. Thrombophillia Screening Guidelines 1. Inherited thrombophilia describes a familial tendency for some individuals to develop. Quality Assurance Program.
Hereditary and Acquired Hypercoagulability : Background, Pathophysiology, Epidemiology. Rosendaal FR. Venous thrombosis: a multicausal disease. Hillarp A, Dahlback B, Zoller B. Activated protein C resistance: from phenotype to genotype and clinical practice. Role of endothelium in thrombosis and hemostasis. Deep vein thrombosis in pregnancy. MCN Am J Matern Child Nurs.
Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). S- 8. 86. S. Antiphospholipid antibodies and the antiphospholipid syndrome. Colman RW, Marder VJ, Clowes AW, et al, eds. Hemostasis and Thrombosis.
Philadelphia, Pa: Lippincott, Williams and Wilkins; 2. Thrombosis and the antiphospholipid syndrome.
Hematology Am Soc Hematol Educ Program. Antiphospholipid antibodies. Clin Adv Hematol Oncol.
Franchini M, Mannucci PM. ABO blood group and thrombotic vascular disease. Heit JA, Cunningham JM, Petterson TM, et al. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. The 1. 9- bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C6. T, Factor V Leiden, prothrombin G2. A polymorphisms in cancer patients with and without thrombosis.
- The Thrombosis and Hemostasis Program at The University of Vermont Medical Center offers. State-of-the-art laboratory diagnostic services for thrombophilia.
- Thrombophilia: Inherited and Acquired. Throughout an entire normal pregnancy, the mother’s ability to produce blood clots in the uterus and the.
- Patients with acquired hypercoagulable states or hereditary thrombophilia are more likely to develop clots, venous thrombosis, and arterial thrombosis.
Activated Protein C Resistance V (APCRV). Mayo Medical Laboratories. Available at http: //www.
Clinical+and+Interpretive/8. Accessed: February 1. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program.
Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. Lijfering WM, Veeger NJ, Middeldorp S, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex- specific risk factors at time of first venous thrombosis in thrombophilic families. Venous thromboembolism and ethnicity.
Inherited risk factors for venous thrombosis. Hematology Am Soc Hematol Educ Program.
Thrombophilia genetics. Colman RW, Marder VJ, Clowes AW, et al, eds. Hemostasis and Thrombosis. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2. Straczek C, Oger E, Yon de Jonage- Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
Antiphospholipid antibodies- -we are not quite there yet. Management of pregnant women with thrombophilia or a history of venous thromboembolism. Hematology Am Soc Hematol Educ Program. Risk of recurrence after venous thromboembolism in men and women: patient level meta- analysis. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.
Heparin and low- molecular- weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. S- 2. 03. S. Agents for the treatment of heparin- induced thrombocytopenia. Hematol Oncol Clin North Am. Adam SS, Mc. Duffie JR, Lachiewicz PF, Ortel TL, Williams JW. Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement . VA Evidence- based Synthesis Program Reports. Novel Anticoagulant Use for Venous Thromboembolism: A 2.
Update. Curr Treat Options Cardiovasc Med. Dobesh PP, Oestreich JH.
Novel Direct- Acting Anticoagulants for Risk Reduction in ACS. The new oral anticoagulants: a challenge for hospital formularies. Use of new- generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta- analysis of randomized controlled trials. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Rajasekhar A, Beyth R, Crowther MA. Newer anticoagulants in critically ill patients. Treatment of established thrombotic events in patients with cancer. Cohen AT, Gurwith MM, Dobromirski M. Thromboprophylaxis in non- surgical cancer patients. Vande Griend JP, Marcum ZA, Linnebur SA.
A year in review: new drugs for older adults in 2. Am J Geriatr Pharmacother. Burke DA, Warraich HJ, Pinto DS.
Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents. Di Nisio M, Middeldorp S, B. Direct thrombin inhibitors. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Is laboratory monitoring of low- molecular- weight heparin therapy necessary?
Is laboratory monitoring of low- molecular- weight heparin therapy necessary? Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Suppl): e. 41. 9S- 9.
S. Measurement of non- coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Correlation of point- of- care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
Welsby IJ, Mc. Donnell E, El- Moalem H, Stafford- Smith M, Toffaletti JG. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. Chang LC, Lee HF, Yang Z, Yang VC.
Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. Schick BP, Maslow D, Moshinski A, San Antonio JD. Novel concatameric heparin- binding peptides reverse heparin and low- molecular- weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Monitoring direct thrombin inhibitors: time for standardization.
New anticoagulants for treatment of venous thromboembolism. I1. 9- 2. 6. Antidote for Factor Xa Anticoagulants. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE- 2): a randomised double- blind trial. Hematol Oncol Clin North Am. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Becattini C, Lignani A, Agnelli G.
New anticoagulants for the prevention of venous thromboembolism. Desai SS, Massad MG, Di.
Domenico RJ, et al. Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past? Recent Pat Cardiovasc Drug Discov. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX. Malherbe S, Tsui BC, Stobart K, Koller J.
Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Powner DJ, Hartwell EA, Hoots WK. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies.